Terns to Present at the UBS Global Healthcare Virtual Conference & Participate in the J.P. Morgan Biotech 2021 CEO Conference Call Series

Rhea-AI Summary

Terns Pharmaceuticals is set to present at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 12:00 p.m. ET, followed by participation in the J.P. Morgan Biotech 2021 CEO Conference Call Series on May 25, 2021, at 1:00 p.m. ET. A live audio webcast will be accessible on the company’s investor page, with a 30-day archive available post-event. Terns specializes in developing small-molecule therapy candidates for non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. For more details, visit their official website.

FOSTER CITY, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that management will be presenting at the UBS Global Healthcare Virtual Conference on Monday, May 24 at 12:00 p.m. ET, and participating in the J.P. Morgan Biotech 2021 CEO Conference Call Series on Tuesday, May 25 at 1:00 p.m. ET.

A live audio webcast of the events will be available on the investors page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on Terns’ website for 30 days following the presentation. J.P. Morgan Biotech 2021 CEO Conference Call Series webcasts require registration.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns’ programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. For more information, please visit www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
investors@ternspharma.com

Media
media@ternspharma.com

FAQ

When is Terns Pharmaceuticals presenting at the UBS Global Healthcare Virtual Conference?

Terns Pharmaceuticals will present at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 12:00 p.m. ET.

What is the date and time for the J.P. Morgan Biotech 2021 CEO Conference Call featuring Terns?

Terns will participate in the J.P. Morgan Biotech 2021 CEO Conference Call Series on May 25, 2021, at 1:00 p.m. ET.

Where can I access the live webcast of Terns Pharmaceuticals' presentations?

The live audio webcast of Terns Pharmaceuticals' presentations can be accessed on the investors page of their official website.

Is there a replay available for Terns Pharmaceuticals' conference presentations?

Yes, a replay of Terns Pharmaceuticals' webcasts will be archived on their website for 30 days following the presentations.

What is Terns Pharmaceuticals' focus in drug development?

Terns Pharmaceuticals focuses on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and other chronic liver diseases.